Home LiteratureArticle Details
PMID: 28417112 Published · ppublish English Journal Article

Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.

Science immunology ·Vol. 1 ·No. 2 ·2016-08-00

Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, Tcyganov E, Hashimoto A, Nefedova Y, Lin C, Partlova S, Garfall A, Vogl DT, Xu X, Knight SC, Malietzis G, Lee GH, Eruslanov E, Albelda SM, Wang X, Mehta JL, Bewtra M, Rustgi A, Hockstein N, Witt R, Masters G, Nam B, Smirnov D, Sepulveda MA, Gabrilovich DI

Abstract

Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are important regulators of immune responses in cancer and have been directly implicated in promotion of tumor progression. However, the heterogeneity of these cells and lack of distinct markers hampers the progress in understanding of the biology and clinical importance of these cells. Using partial enrichment of PMN-MDSC with gradient centrifugation we determined that low density PMN-MDSC and high density neutrophils from the same cancer patients had a distinct gene profile. Most prominent changes were observed in the expression of genes associated with endoplasmic reticulum (ER) stress. Surprisingly, low-density lipoprotein (LDL) was one of the most increased regulators and its receptor oxidized LDL receptor 1 OLR1 was one of the most overexpressed genes in PMN-MDSC. Lectin-type oxidized LDL receptor 1 (LOX-1) encoded by OLR1 was practically undetectable in neutrophils in peripheral blood of healthy donors, whereas 5-15% of total neutrophils in cancer patients and 15-50% of neutrophils in tumor tissues were LOX-1+. In contrast to their LOX-1- counterparts, LOX-1+ neutrophils had gene signature, potent immune suppressive activity, up-regulation of ER stress, and other biochemical characteristics of PMN-MDSC. Moreover, induction of ER stress in neutrophils from healthy donors up-regulated LOX-1 expression and converted these cells to suppressive PMN-MDSC. Thus, we identified a specific marker of human PMN-MDSC associated with ER stress and lipid metabolism, which provides new insight to the biology and potential therapeutic targeting of these cells.

Authors & Affiliations
30 authors, click to expand affiliations / ORCID
Condamine Thomas
The Wistar Institute, Philadelphia, PA, 19104, USA.
Dominguez George A
The Wistar Institute, Philadelphia, PA, 19104, USA.
Youn Je-In
The Wistar Institute, Philadelphia, PA, 19104, USA.
Kossenkov Andrew V
The Wistar Institute, Philadelphia, PA, 19104, USA.
Mony Sridevi
The Wistar Institute, Philadelphia, PA, 19104, USA.
Alicea-Torres Kevin
The Wistar Institute, Philadelphia, PA, 19104, USA.
Tcyganov Evgenii
The Wistar Institute, Philadelphia, PA, 19104, USA.
Hashimoto Ayumi
The Wistar Institute, Philadelphia, PA, 19104, USA.
Nefedova Yulia
The Wistar Institute, Philadelphia, PA, 19104, USA.
Lin Cindy
The Wistar Institute, Philadelphia, PA, 19104, USA.
Partlova Simona
The Wistar Institute, Philadelphia, PA, 19104, USA.
Garfall Alfred
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104, USA. | Division of Gastroenterology, Departments of Medicine and Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Vogl Dan T
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104, USA. | Division of Gastroenterology, Departments of Medicine and Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Xu Xiaowei
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104, USA. | Division of Gastroenterology, Departments of Medicine and Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Knight Stella C
Antigen Presentation Research Group, Imperial College London, London, UK HA1 3UJ.
Malietzis George
Antigen Presentation Research Group, Imperial College London, London, UK HA1 3UJ. | St. Mark's Hospital, Harrow, UK, HA1 3UJ.
Lee Gui Han
Antigen Presentation Research Group, Imperial College London, London, UK HA1 3UJ. | St. Mark's Hospital, Harrow, UK, HA1 3UJ.
Eruslanov Evgeniy
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Albelda Steven M
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104, USA. | Division of Gastroenterology, Departments of Medicine and Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Wang Xianwei
Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Mehta Jawahar L
Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Bewtra Meenakshi
Division of Gastroenterology, Departments of Medicine and Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Rustgi Anil
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, 19104, USA. | Division of Gastroenterology, Departments of Medicine and Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Hockstein Neil
Helen F. Graham Cancer Center & Research Institute, Christiana Care Health System, Newark, DE 19713, USA.
Witt Robert
Helen F. Graham Cancer Center & Research Institute, Christiana Care Health System, Newark, DE 19713, USA.
Masters Gregory
Helen F. Graham Cancer Center & Research Institute, Christiana Care Health System, Newark, DE 19713, USA.
Nam Brian
Helen F. Graham Cancer Center & Research Institute, Christiana Care Health System, Newark, DE 19713, USA.
Smirnov Denis
Janssen Oncology Therapeutic Area, Janssen Research and Development, LLC, Pharmaceutical Companies of Johnson & Johnson, Spring House, PA, 19477, USA.
Sepulveda Manuel A
Janssen Oncology Therapeutic Area, Janssen Research and Development, LLC, Pharmaceutical Companies of Johnson & Johnson, Spring House, PA, 19477, USA.
Gabrilovich Dmitry I
The Wistar Institute, Philadelphia, PA, 19104, USA.
References (52)
52 references, click to expand
  1. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.
    Cancer Immunol Immunother. 2009 Jan;58(1):49-59 PMID: 18446337
  2. From endoplasmic-reticulum stress to the inflammatory response.
    Nature. 2008 Jul 24;454(7203):455-62 PMID: 18650916
  3. LOX-1: a multiligand receptor at the crossroads of response to danger signals.
    Curr Opin Lipidol. 2012 Oct;23(5):439-45 PMID: 22777292
  4. Cell-extrinsic effects of tumor ER stress imprint myeloid dendritic cells and impair CD8⁺ T cell priming.
    PLoS One. 2012;7(12):e51845 PMID: 23272178
  5. A comprehensive evaluation of SAM, the SAM R-package and a simple modification to improve its performance.
    BMC Bioinformatics. 2007 Jun 29;8:230 PMID: 17603887
  6. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.
    Cancer Prev Res (Phila). 2013 Jan;6(1):18-26 PMID: 23248097
  7. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45 PMID: 19572148
  8. Transcriptional regulation of myeloid-derived suppressor cells.
    J Leukoc Biol. 2015 Dec;98 (6):913-22 PMID: 26337512
  9. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.
    J Clin Invest. 2015 Sep;125(9):3356-64 PMID: 26168215
  10. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.
    J Clin Invest. 2014 Jun;124(6):2626-39 PMID: 24789911
  11. Translational control in stress and apoptosis.
    Nat Rev Mol Cell Biol. 2005 Apr;6(4):318-27 PMID: 15803138
  12. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
    PLoS One. 2014 Feb 03;9(2):e87705 PMID: 24498358
  13. Clinical and Preclinical Use of LOX-1-Specific Antibodies in Diagnostics and Therapeutics.
    J Cardiovasc Transl Res. 2015 Nov;8(8):458-65 PMID: 26385009
  14. Tumor stress inside out: cell-extrinsic effects of the unfolded protein response in tumor cells modulate the immunological landscape of the tumor microenvironment.
    J Immunol. 2011 Nov 1;187(9):4403-9 PMID: 22013206
  15. On the armament and appearances of human myeloid-derived suppressor cells.
    Clin Immunol. 2012 Sep;144(3):250-68 PMID: 22858650
  16. Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients.
    J Immunother. 2014 Jan;37(1):43-50 PMID: 24316555
  17. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study.
    Cancer Immunol Immunother. 2016 Feb;65(2):161-9 PMID: 26728481
  18. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.
    J Immunol. 2013 Apr 1;190(7):3815-23 PMID: 23460744
  19. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.
    Am J Respir Crit Care Med. 2012 Nov 15;186(10):1025-36 PMID: 22955317
  20. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
    J Immunol Res. 2014;2014:659294 PMID: 25436215
  21. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet.
    Circ Res. 2007 Jun 8;100(11):1634-42 PMID: 17478727
  22. The discovery of LOX-1, its ligands and clinical significance.
    Cardiovasc Drugs Ther. 2011 Oct;25(5):379-91 PMID: 21805404
  23. Ox-LDL induces endothelial cell apoptosis via the LOX-1-dependent endoplasmic reticulum stress pathway.
    Atherosclerosis. 2014 Aug;235(2):310-7 PMID: 24911634
  24. Coordinated regulation of myeloid cells by tumours.
    Nat Rev Immunol. 2012 Mar 22;12(4):253-68 PMID: 22437938
  25. Transmission of endoplasmic reticulum stress and pro-inflammation from tumor cells to myeloid cells.
    Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6561-6 PMID: 21464300
  26. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils.
    PLoS One. 2012;7(2):e31524 PMID: 22348096
  27. Statistical significance for genomewide studies.
    Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 PMID: 12883005
  28. Lectin-like oxidized low-density lipoprotein receptor 1 pathways.
    Eur J Clin Invest. 2013 Jul;43(7):740-5 PMID: 23594336
  29. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy.
    Cancer Immunol Immunother. 2015 Jan;64(1):1-13 PMID: 25432147
  30. LOX-1 and angiotensin receptors, and their interplay.
    Cardiovasc Drugs Ther. 2011 Oct;25(5):401-17 PMID: 21861069
  31. Signal integration in the endoplasmic reticulum unfolded protein response.
    Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29 PMID: 17565364
  32. Oxidized LDL and LOX-1 in experimental sepsis.
    Mediators Inflamm. 2013;2013:761789 PMID: 24000272
  33. Elevated endoplasmic reticulum stress reinforced immunosuppression in the tumor microenvironment via myeloid-derived suppressor cells.
    Oncotarget. 2014 Dec 15;5(23):12331-45 PMID: 25514597
  34. Subsets of myeloid-derived suppressor cells in tumor-bearing mice.
    J Immunol. 2008 Oct 15;181(8):5791-802 PMID: 18832739
  35. Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions.
    Immunol Lett. 1999 May 3;68(1):125-34 PMID: 10397167
  36. Mapping the crossroads of immune activation and cellular stress response pathways.
    EMBO J. 2013 May 2;32(9):1214-24 PMID: 23584529
  37. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma.
    J Immunother. 2010 Oct;33(8):817-27 PMID: 20842055
  38. LOX-1, OxLDL, and atherosclerosis.
    Mediators Inflamm. 2013;2013:152786 PMID: 23935243
  39. Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis.
    Antioxid Redox Signal. 2011 Oct 15;15(8):2301-33 PMID: 21338316
  40. Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.
    J Clin Invest. 2014 Jun;124(6):2585-98 PMID: 24812669
  41. High-Density Lipoprotein Prevents Endoplasmic Reticulum Stress-Induced Downregulation of Liver LOX-1 Expression.
    PLoS One. 2015 Apr 29;10 (4):e0124285 PMID: 25923692
  42. Neutrophilic inflammatory response and oxidative stress in premenopausal women chronically exposed to indoor air pollution from biomass burning.
    Inflammation. 2012 Apr;35(2):671-83 PMID: 21769440
  43. Regulation of tumor metastasis by myeloid-derived suppressor cells.
    Annu Rev Med. 2015;66:97-110 PMID: 25341012
  44. Endoplasmic reticulum stress in immunity.
    Annu Rev Immunol. 2015;33:107-38 PMID: 25493331
  45. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases.
    Cancer Cell. 2010 Apr 13;17(4):348-61 PMID: 20385360
  46. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Trends Immunol. 2016 Mar;37(3):208-20 PMID: 26858199
  47. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
    Cancer Immunol Immunother. 2014 Mar;63(3):247-57 PMID: 24357148
  48. The unfolded protein response: from stress pathway to homeostatic regulation.
    Science. 2011 Nov 25;334(6059):1081-6 PMID: 22116877
  49. An endothelial receptor for oxidized low-density lipoprotein.
    Nature. 1997 Mar 6;386(6620):73-7 PMID: 9052782
  50. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Int Immunopharmacol. 2011 Jul;11(7):856-61 PMID: 21315783
  51. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors.
    Immunity. 2014 Sep 18;41(3):389-401 PMID: 25238096
  52. LOX-1: a new target for therapy for cardiovascular diseases.
    Cardiovasc Drugs Ther. 2011 Oct;25(5):495-500 PMID: 21826406
Article Info
Journal
Science immunology
Abbr.
Sci Immunol
ISSN
2470-9468
Published
2016-08-00
Epub
2016-00-05
Language
English
Region
United States
NLM ID
101688624
PMCID
PMC5391495
Grants
NCI NIH HHS · R01 CA187392 · United States
NCI NIH HHS · R01 CA165065 · United States
NCI NIH HHS · R01 CA084488 · United States
NCI NIH HHS · R50 CA211199 · United States
NCI NIH HHS · P01 CA098101 · United States
NCI NIH HHS · R01 CA100062 · United States
NCI NIH HHS · T32 CA009171 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]